Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) kicked off on Tuesday, up 1.48% from the previous trading day, before settling in for the closing price of $440.66. Over the past 52 weeks, VRTX has traded in a range of $377.85-$519.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 22.39%. While this was happening, its average annual earnings per share was recorded 4182.49%. With a float of $256.00 million, this company’s outstanding shares have now reached $256.97 million.
Let’s determine the extent of company efficiency that accounts for 6100 employees. In terms of profitability, gross margin is 86.01%, operating margin of -6.79%, and the pretax margin is -2.71%.
Vertex Pharmaceuticals, Inc (VRTX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Vertex Pharmaceuticals, Inc is 0.31%, while institutional ownership is 95.09%. The most recent insider transaction that took place on May 15 ’25, was worth 22,084. In this transaction EVP, Chief Scientific Officer of this company sold 52 shares at a rate of $424.69, taking the stock ownership to the 23,281 shares. Before that another transaction happened on May 15 ’25, when Company’s Officer proposed sale 52 for $424.69, making the entire transaction worth $22,084.
Vertex Pharmaceuticals, Inc (VRTX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 4182.49% per share during the next fiscal year.
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) Trading Performance Indicators
Take a look at Vertex Pharmaceuticals, Inc’s (VRTX) current performance indicators. Last quarter, stock had a quick ratio of 2.29. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.92, a number that is poised to hit 4.30 in the next quarter and is forecasted to reach 20.89 in one year’s time.
Technical Analysis of Vertex Pharmaceuticals, Inc (VRTX)
Looking closely at Vertex Pharmaceuticals, Inc (NASDAQ: VRTX), its last 5-days average volume was 1.64 million, which is a drop from its year-to-date volume of 1.66 million. As of the previous 9 days, the stock’s Stochastic %D was 71.56%. Additionally, its Average True Range was 14.55.
During the past 100 days, Vertex Pharmaceuticals, Inc’s (VRTX) raw stochastic average was set at 40.78%, which indicates a significant increase from 33.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.96% in the past 14 days, which was higher than the 30.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $481.62, while its 200-day Moving Average is $468.30. However, in the short run, Vertex Pharmaceuticals, Inc’s stock first resistance to watch stands at $449.85. Second resistance stands at $452.52. The third major resistance level sits at $457.04. If the price goes on to break the first support level at $442.66, it is likely to go to the next support level at $438.14. Now, if the price goes above the second support level, the third support stands at $435.47.
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) Key Stats
The company with the Market Capitalisation of 114.83 billion has total of 256,797K Shares Outstanding. Its annual sales at the moment are 11,020 M in contrast with the sum of -535,600 K annual income. Company’s last quarter sales were recorded 2,770 M and last quarter income was 646,300 K.
